Skip to main content
. 2021 Mar 9;11:562135. doi: 10.3389/fonc.2021.562135

Figure 2.

Figure 2

The cost-effectiveness acceptability curves for HAIC plus sorafenib strategy compared to the sorafenib strategy. HAIC, hepatic arterial infusion chemotherapy; WTP, willingness-to-pay.